OpenNashEarnings

Pharmaceuticals · NYSE: GSK

GSK earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 3 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

GSK is leaning on new specialty launches and 22 Phase III starts this year, with Hibsago approved in the US and Japan as a potential functional cure for chronic hepatitis B.

Specialty medicines drove the quarter. Long-acting HIV injectables supplied most of HIV growth, Nucala gained from its COPD launch, and Exdensur and Blenrep kept widening access. Jideytro became GSK's first lung cancer medicine, and Hibsago, Jemperli and Jideytro all won US approvals. Vaccines were weaker: Shingrix fell on China destocking and Arexvy on lower market demand, while meningitis vaccines had a record quarter.

Read the Q3 2026 summary →

Quarters

KPI history

20-F filings